Why is Ajanta Pharma Ltd. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 22.01%
- Company has a low Debt to Equity ratio (avg) at 0 times
2
With a growth in Operating Profit of 51.08%, the company declared Very Positive results in Sep 26
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 33.93%
- NET SALES(Q) Highest at Rs 1,794.16 cr
- PBDIT(Q) Highest at Rs 547.56 cr.
3
Stock is technically in a Mildly Bullish range
- The stocks MACD and KST technical factors are also Bullish
4
High Institutional Holdings at 29.57%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
6
Market Beating Performance
- The stock has generated a return of 31.98% in the last 1 year, much higher than market (BSE500) returns of 0.37%
How much should you buy?
- Overall Portfolio exposure to Ajanta Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ajanta Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Ajanta Pharma
31.98%
1.21
26.52%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
14.65%
EBIT Growth (5y)
11.80%
EBIT to Interest (avg)
89.20
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
1.13
Tax Ratio
25.17%
Dividend Payout Ratio
33.24%
Pledged Shares
20.65%
Institutional Holding
29.57%
ROCE (avg)
30.05%
ROE (avg)
22.01%
Valuation Key Factors 
Factor
Value
P/E Ratio
33
Industry P/E
40
Price to Book Value
8.51
EV to EBIT
27.09
EV to EBITDA
24.19
EV to Capital Employed
9.42
EV to Sales
6.56
PEG Ratio
1.10
Dividend Yield
0.97%
ROCE (Latest)
34.76%
ROE (Latest)
25.99%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Movement
24What is working for the Company
ROCE(HY)
Highest at 33.93%
NET SALES(Q)
Highest at Rs 1,794.16 cr
PBDIT(Q)
Highest at Rs 547.56 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 30.52%
PBT LESS OI(Q)
Highest at Rs 497.76 cr.
PAT(Q)
Highest at Rs 388.14 cr.
EPS(Q)
Highest at Rs 30.96
-2What is not working for the Company
OPERATING CF(Y)
Lowest at Rs 529.19 Cr
Loading Valuation Snapshot...
Here's what is working for Ajanta Pharma
Net Sales - Quarterly
Highest at Rs 1,794.16 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 497.76 cr has Grown at 76.84%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 388.14 cr has Grown at 49.2%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 1,794.16 cr has Grown at 32.53%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 547.56 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 30.52%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 497.76 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 388.14 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 30.96
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Ajanta Pharma
Operating Cash Flow - Annually
Lowest at Rs 529.19 Cr
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (Rs Cr)